MUMBAI, India, November 10 /PRNewswire/ --

- Ashorne Hill and Tata Interactive Systems Join Hands to Enable Key Organisational Initiatives

Now both Ashorne Hill and Tata Interactive Systems, part of the $70 billion Tata Group, have come together to provide a range of bespoke Learning Solutions designed to help organisations address and support key business challenges.

Announcing the alliance, John Carson, Managing Director of Ashorne Hill said, The combination of Ashorne Hill's highly experienced Learning Development capability and Tata Interactive Systems' Learning Technology expertise will enable us to support our clients with solutions that enable employees to impact and deliver measurable results back into the business.

SAN FRANCISCO, November 10 /PRNewswire/ --

- Find out what's hot in Hollywood at blinkx.com

blinkx, the world's largest video search engine, today announced a content partnership with People.com, the leading celebrity news site. Under the terms of the agreement, blinkx has added People.com's high-quality, original video programming to its ever-expanding index.

OSLO and FOSTER CITY, California, November 10 /PRNewswire/ --

- India Chosen as First Commercial Market to Demonstrate Test's Potential for Rapid Uptake

DiaGenic ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI) today announced the launch of BCtect(TM), a blood-based test for early detection of breast cancer. The test searches for a unique gene expression signature identified by DiaGenic using a custom TaqMan(R) Array manufactured for DiaGenic by Applied Biosystems. India was chosen as the first country for the introduction of BCtect(TM) after successful completion of a large study in the country.

NOVATO, California, November 10 /PRNewswire/ --

Raptor Pharmaceuticals Corp. (Raptor or the Company) (OTC Bulletin Board: RPTP), today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers (CHU d'Angers) of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate (DR Cysteamine) in a Phase II clinical trial in patients with Huntington's Disease (Huntington's). CHU d'Angers has received a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health, to fund the two-year, multi-center Phase II clinical trial in Huntington's patients. Under the terms of the agreement, Raptor will provide clinical supplies of DR Cysteamine for the trial.

CAMBRIDGE, England, November 10 /PRNewswire/ --

- The European Hands-On Science Research Programme Brings the Amgen Foundation's Total Commitment to Amgen Scholars to 27.5 Million USD

The Amgen Foundation and the University of Cambridge, along with two other leading European universities, today announced the launch of Amgen Scholars Europe, a 2.5 million USD, two-year programme that will provide more than 100 selected undergraduate students from throughout Europe the opportunity to engage in a hands-on summer research experience under top academic scientists at three world class universities.

BASEL, Switzerland, November 10 /PRNewswire/ --

- Results Demonstrate Effective and Simplified Approach to Anaemia Management in Chronic Kidney Disease Patients on Dialysis

Interim study results from 90 renal centres in Germany confirm for the first time that in a real-life setting Mircera(R) maintains haemoglobin (Hb) levels within a narrow range when chronic kidney disease (CKD) patients receiving dialysis are switched to once-monthly Mircera from commonly used and frequently dosed erythropoiesis-stimulating agents (ESAs)(1).

Multimedia News Release: http://www.prnewswire.com/mnr/mircera/35922/

LONDON, November 10 /PRNewswire/ --

Global warming, energy security and rising oil prices have resuscitated the marine energy sector. Ocean energy is a predictable and abundant source of energy with the ability to supply approximately 10% of the world's electricity needs.

The value of worldwide electricity revenues from wave and tidal stream projects could ultimately be between pounds sterling 60bn (euro 77.40bn) and pounds sterling 190bn (euro 245.10bn) per year. The United Kingdom is a clear leader both in terms of activity and in terms of support to the sector. It possesses 50% of Europe's wave energy potential.

Petroleum is the feedstock for many products in the chemical industry but it is becoming increasingly expensive.  Renewable raw materials are an alternative but we quickly learned that, despite the beliefs of activists in the 1980s and 1990s, fuel from food was not a good idea.

Thanks to white industrial biotechnology, chemical substances can also be derived from waste products generated by the food industry, leftover biomass from agriculture and forestry, and residual materials. Researchers of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart are demonstrating how this biotechnical recycling works, using colza, whey and crab shells as examples.

It sounds like a science fiction movie: A killer contagion threatens the Earth, but scientists save the day with a designer drug that forces the virus to mutate itself out of existence. The killer disease? Still a fiction. The drug? It could become a reality thanks to a new study by Rice University bioengineers.

The study, which is available online and slated for publication in the journal Physical Review E, offers the most comprehensive mathematical analysis to date of the mechanisms that drive evolution in viruses and bacteria. Rather than focusing solely on random genetic mutations, as past analyses have, the study predicts exactly how evolution is affected by the exchange of entire genes and sets of genes.

Children with heart defects may someday receive perfectly-matched new heart valves built using stem cells from their umbilical cord blood, according to research presented at the American Heart Association's Scientific Sessions 2008.

When infants are born with malfunctioning heart valves that can't be surgically repaired, they rely on replacements from animal tissue, compatible human organ donations or artificial materials. These replacements are lifesaving, but don't grow and change shape as a child develops; so two or more surgeries may be needed to replace outgrown valves. The animal tissue may also stiffen over time as well and be less durable than a normal human valve.